4d
Hosted on MSNBarclays Downgrades Illumina (ILMN)Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...
For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...
Shares of Illumina Inc. ILMN shed 1.51% to $100.24 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...
Carl Icahn’s Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund increased its stakes in two holdings, ...
On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...
Shares of Illumina Inc. ILMN slipped 4.11% to $100.68 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 6,068.50 ...
However, 10 companies defied a broader market optimism, mostly due to a series of stock rating downgrades from investment ...
Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively. We recently published a list of Jim ...
Illumina (NASDAQ:ILMN – Free Report) had its price objective cut by Canaccord Genuity Group from $145.00 to $135.00 in a report published on Friday,Benzinga reports. They currently have a hold rating ...
2d
Hosted on MSNHere's Why Illumina (ILMN) is a Strong Growth StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Regeneron and Illumina have joined a major investment ... will use leftover biospecimens from routine lab tests to sequence up to ten million exomes – all of the exons in a genome that code ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results